Corcept Therapeutics (CORT) insider notifies sale of 40,000 shares via Stifel
Filing Impact
Filing Sentiment
Form Type
144
Rhea-AI Filing Summary
Corcept Therapeutics reported a proposed sale of 40,000 shares of Common Stock under Rule 144 via broker Stifel Nicolaus & Company Inc.. The filing also records a prior sale of 26,198 shares on 03/25/2026 for $1,311,825.
Positive
- None.
Negative
- None.
Key Figures
Proposed shares to be sold: 40,000 shares
Aggregate amount shown nearby: $1,860,800.00
Shares sold in past 3 months: 26,198 shares
+2 more
5 metrics
Proposed shares to be sold
40,000 shares
Rule 144 proposed sale listed on the filing
Aggregate amount shown nearby
$1,860,800.00
Numeric value appearing on the broker/security line in the excerpt
Shares sold in past 3 months
26,198 shares
Sale dated 03/25/2026 listed under "Securities Sold During The Past 3 Months"
Proceeds from prior sale
$1,311,825.00
Proceeds shown for the 03/25/2026 sale of 26,198 shares
Broker listed
Stifel Nicolaus & Company Inc.
Broker handling the proposed sale as shown on the filing
Key Terms
Rule 144, Stock Option Exercise, Securities Sold During The Past 3 Months
3 terms
Rule 144 regulatory
"proposed sale of 40,000 shares under Rule 144"
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Stock Option Exercise financial
"07/06/2022 | Stock Option Exercise | Corcept Therapeutics Inc."
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.
Securities Sold During The Past 3 Months financial
"Common | 03/25/2026 | 26198 | 1311825.00"
FAQ
Who filed the Form 144 for Corcept Therapeutics (CORT)?
The Form 144 lists Joseph K. Belanoff as the reporting person. The filing names Stifel Nicolaus & Company Inc. as the broker handling the proposed sale of shares under Rule 144.
Does the Form 144 show any recent sales by the same holder for CORT?
Yes. The filing records a prior sale of 26,198 shares on 03/25/2026 with proceeds shown as $1,311,825. That sale is listed under "Securities Sold During The Past 3 Months."
What trade method or reason is listed for the securities in the Form 144?
The excerpt includes the phrase "Stock Option Exercise" dated 07/06/2022 and lists Cash as the method. The present Form 144, however, reports the proposed resale quantities and broker routing.
Which broker and exchange are named in the Corcept (CORT) Form 144?
The filing names Stifel Nicolaus & Company Inc. with an address in St. Louis and indicates NASDAQ as the exchange. Broker details appear on the broker/"Securities To Be Sold" line of the notice.